, Volume 174, Issue 1, pp 54–64 | Cite as

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

  • Laura F. Martin
  • William R. Kem
  • Robert Freedman


Rationale and objective

Auditory sensory gating, a biological measurement of the ability to suppress the evoked response to the second of two auditory stimuli, is diminished in people with schizophrenia. Deficits in sensory gating are associated with attentional impairment, and may contribute to cognitive symptoms and perceptual disturbances. This inhibitory process, which involves the alpha7 nicotinic receptor mediated release of gamma-aminobutyric acid (GABA) by hippocampal interneurons, represents a potential new target for therapeutic intervention in schizophrenia.


This paper will review several lines of evidence implicating the nicotinic-cholinergic, and specifically, the alpha7 nicotinic receptor system in the pathology of schizophrenia and the evidence that alpha7 nicotinic receptor agonists may ameliorate some of these deficits.


Impaired auditory sensory gating has been linked to the alpha7 nicotinic receptor gene on the chromosome 15q14 locus. Single nucleotide polymorphisms of the promoter region of this gene are more frequent in people with schizophrenia. Although nicotine can acutely reverse diminished auditory sensory gating in people with schizophrenia, this effect is lost on a chronic basis due to receptor desensitization. Clozapine is able to reverse auditory sensory gating impairment, probably through an alpha7 nicotinic receptor mechanism, in both humans and animal models with repeated dosing. The alpha7 nicotinic agonist 3-2,4 dimethoxybenzylidene anabaseine (DMXBA) can also enhance auditory sensory gating in animal models. DMXBA is well tolerated in humans and improves several cognitive measures.


Alpha-7 nicotinic receptor agonists appear to be reasonable candidates for the treatment of cognitive and perceptual disturbances in schizophrenia.


Auditory evoked potentials Nicotinic receptors Investigational drugs Antipsychotic agents Schizophrenia 


  1. Adams CE, Stevens KE, Kem WR, Freedman R (2000) Inhibition of nitric oxide synthase prevents alpha7 nicotinic receptor-mediated restoration of inhibitory auditory gating in rat hippocampus. Brain Res 877:235–44CrossRefPubMedGoogle Scholar
  2. Adler LE, Waldo MC, Freedman R (1985) Neurophysiologic studies of sensory gating in schizophrenia: comparison of auditory and visual responses. Biol Psychiatry 20:1284–1296PubMedGoogle Scholar
  3. Adler LE, Hoffer LD, Griffith J, Waldo MC, Freedman R (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32:607–616PubMedGoogle Scholar
  4. Adler LE, Hoffer LD, Wiser A, Freedman R (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150:1856–1861PubMedGoogle Scholar
  5. Adler LE, Olincy A, Waldo MC, Harris JG, Griffith J, Stevens KE, Flach K, Nagamoto HT, Bickford PC, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189–202PubMedGoogle Scholar
  6. Albuquerque EX, Pereira EFR, Braga MFM, Alkondon M (1998) Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha7 receptors. J Physiol (Paris) 92:309–316Google Scholar
  7. Albuquerque EX, Pereira EFR, Mike A, Eisenbreg HM, Maelicke A, Alkondon M (2000) Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance. Behav Brain Res 113:131–141CrossRefPubMedGoogle Scholar
  8. Alkondon M, Braga MFM, Pereira EFR, Maelicke A, Albuquerque EX (2000) Alpha-7 nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 393:59–67CrossRefPubMedGoogle Scholar
  9. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252–259CrossRefPubMedGoogle Scholar
  10. Armitage AK, Hall GH, Sellers CM (1969) Effects of nicotine on electrocortical activity and acetylcholine release from the cat cerebral cortex. Br J Pharmacol 35:152–160PubMedGoogle Scholar
  11. Balfour DJK (1989) Influence of nicotine on the release of monoamines in the brain. Prog Brain Res 79:165–172PubMedGoogle Scholar
  12. Beani L, Bianchi C, Ferraro L, Nilsson L, Nordberg A, Romanelli L, Spalluto P, Sundwall A, Tanganelli S (1989) Effect of nicotine on the release of acetylcholine and amino acids in the brain. Prog Brain Res 79:149–155PubMedGoogle Scholar
  13. Benowitz NL (1998) Summary: risks and benefits of nicotine. In: Benowitz NL (ed) Nicotine safety and toxicity. Oxford University Press, New York, pp 185–88Google Scholar
  14. Benowitz NL (2003) Basic cardiovascular research and its implications for the medicinal use of nicotine. J Am Coll Cardiol 41:497–498CrossRefPubMedGoogle Scholar
  15. Benowitz NL, Gourlay SG (1997) Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Acad Cardiol 29:1422–1431Google Scholar
  16. Bhagat B, Kramer SZ (1967) The effects of nicotine and other drugs on the release of injected 3H-norepinephrine and on endogenous norepinephrine levels in the rat brain. Eur J Pharmacol 2:234–235CrossRefPubMedGoogle Scholar
  17. Bickford PC, Wear KD (1995) Restoration of sensory gating of auditory evoked response by nicotine in fimbria-fornix lesioned rats. Brain Res 705:235–240CrossRefPubMedGoogle Scholar
  18. Boutros NN, Zouridakis G, Overall J (1991) Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 22:40–45PubMedGoogle Scholar
  19. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S (2000) Abnormal regulation of high affinity nicotine receptors in subjects with schizophrenia. Neuropsychopharmacology 23:351–364CrossRefPubMedGoogle Scholar
  20. Briggs CA, McKenna DG, Piattoni-Kaplan M (1995) Human alpha7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34:583–590CrossRefPubMedGoogle Scholar
  21. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliot RL, Gopalakrishnan M, Holladay MW, Hui Y-H, Jackson WJ, Kim DJB, Marsh KC, O’Neill A, Prendergast MA, Ryther KB, Sullivan JP, Arneric SP (1996) Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57:231–241CrossRefGoogle Scholar
  22. Broide RS, Leslie FM (1999) The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 20:1–16PubMedGoogle Scholar
  23. Chalon S, Moreno Jr H, Benowitz NL, Hoffman BB, Blaschke TF (2000) Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther 67:391–397CrossRefPubMedGoogle Scholar
  24. Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretti M, Heinemann S (1994) Molecular cloning and chromosomal localization of the human alpha7-nicotinic receptor subunit gene (CHRNA7). Genomics 19:379–381CrossRefPubMedGoogle Scholar
  25. Clementz BA (1998) Psychophysiological measures of (dis)inhibition as liability indicators for schizophrenia. Psychophysiology 35:648–668Google Scholar
  26. Clementz BA, Geyer MA, Braff DL (1997) P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry 41:1035–1044CrossRefPubMedGoogle Scholar
  27. Clementz BA, Geyer MA, Braff DL (1998) Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry 155:1691–1694PubMedGoogle Scholar
  28. Combs DR, Advokat C (2000) Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res 46:129–137CrossRefPubMedGoogle Scholar
  29. Coon H, Plaetke R, Holik J, Hoff M, Myles-Worsley M, Waldo MC, Freedman R, Byerley W (1993) Use of a neurophysiological trait in linkage analysis of schizophrenia. Biol Psychiatry 34:277–289CrossRefPubMedGoogle Scholar
  30. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E (1999) Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in thalamus. J Neurochem 73:1590–1597CrossRefPubMedGoogle Scholar
  31. Court J, Piggot M, Lloyd S, Cookson N, Ballard C, McKeith I, Perry R, Perry E (2000) Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience 98:79–87CrossRefPubMedGoogle Scholar
  32. Craddock N, Lendon C (1999) Chromosome workshop: chromosomes 11, 14, and 15. Am J Med Genet 88:244–54CrossRefPubMedGoogle Scholar
  33. Crowley-Weber CL, Dvorakova K, Crowley C, Bernstein H, Bernstein C, Garewal H, Payne CM (2003) Nicotine increases oxidative stress, activates NF-kB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem-Biol Interact 145:53–66Google Scholar
  34. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R (1993) Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 10:131–141CrossRefPubMedGoogle Scholar
  35. Curtis L, Blouin J-L, Radhakrishna U, Gehrig C, Lasseter VK, Wolyniec P, Nestadt G, Dombroski B, Kazazian HH, Pulver AE, Housman D, Bertrand D, Antonarakis SE (1999) No evidence for linkage between schizophrenia and markers at chromosome 15q13–14. Am J Med Genet 88:109–112PubMedGoogle Scholar
  36. Dalack GW, Meador-Woodruff JH (1996) Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res 22:133–141CrossRefPubMedGoogle Scholar
  37. Dalack GW, Healy DJ, Meador-Woodruff JH (1998) Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155:1490–1501PubMedGoogle Scholar
  38. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH (1999) Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 21:195–202CrossRefPubMedGoogle Scholar
  39. Damaj MI, Glassco W, Dukat M, Martin BR (1999) Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 291:1284–1291PubMedGoogle Scholar
  40. De Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL (1995) Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha7/125 i-alpha-bungarotoxin receptor subtypes. Mol Pharmacol 47:164–171PubMedGoogle Scholar
  41. De Leon J, Dadvand M, Canuso C, Odom White A, Stanilla JK, Simpson GM (1995) Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 152:453–455PubMedGoogle Scholar
  42. Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P (1990) Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatry 28:502–508CrossRefPubMedGoogle Scholar
  43. Dépatie L, O’Driscoll GA, Holahan A, Atkinson V, Thayundayil JX, Kin N, Lal S (2002) Nicotine and behavioral markers of risk for schizophrenia: a double blind, placebo controlled, cross-over study. Neuropsychopharmacology 27:1056–1970CrossRefPubMedGoogle Scholar
  44. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW (1998) Differential prevalence of cigarette smoking in patients with schizophrenia vs mood disorders. Schizophr Res 33:113–118CrossRefPubMedGoogle Scholar
  45. Dobelis P, Hutton S, Lu Y, Collins AC (2003) GABAergic systems modulate nicotinic receptor-mediated seizures in mice. J Pharmacol Exp Ther 306:1159–1166CrossRefPubMedGoogle Scholar
  46. Durany N, Zöchling R, Boissl KW, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Deckert J, Riederer P (2000) Human post-mortem striatal alpha4/beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson’s syndrome. Neurosci Lett 287:109–112CrossRefPubMedGoogle Scholar
  47. Elliott BM, Faraday MM, Grunberg NE (2003) Effects of nicotine on heart dimensions and blood volume in male and female rats. Nicotine Tobacco Res 5:341–348CrossRefGoogle Scholar
  48. Fang Q, Sun H, Mayhan WG (2003) Impairment of nitric oxide synthase-dependent dilatation of cerebral arterioles during infusion of nicotine. Am J Physiol-Heart Circ Physiol 284:528–534Google Scholar
  49. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddle TV (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18:1187–1195PubMedGoogle Scholar
  50. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD (1983) Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparisons of medicated and drug-free patients. Biol Psychiatry 18:537–551PubMedGoogle Scholar
  51. Freedman R, Adler LE, Bickford PC, Byerley W, Coon H, Cullum CM, Griffith J, Harris JG, Leonard S, Miller C, Myles-Worsley M, Nagamoto HT, Rose GM, Waldo MC (1994) Schizophrenia and nicotinic receptors. Harvard Rev Psychiatry:179–192Google Scholar
  52. Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22–33Google Scholar
  53. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams CE, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94:587–592PubMedGoogle Scholar
  54. Freedman R, Leonard S, Olincy A, Kaufmann CA, Malaspina D, Cloninger CR, Svrakic DM, Faraone SV, Tsuang MT (2001) Evidence for the multigenic inheritance of schizophrenia. Am J Med Genet 105:794–800CrossRefPubMedGoogle Scholar
  55. George TP, Serynak MJ, Ziedonis DM, Woods SW (1995) Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56:344–346PubMedGoogle Scholar
  56. George TP, Vessicchio JC, Termine A, Sahady D, Head CA, Pepper WT, Kosten TR, Wexler BE (2001) Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26:75–85CrossRefGoogle Scholar
  57. Girod R, Jareb M, Moss J, Role L (2003) Mapping of presynaptic nicotinic acetylcholine receptors using fluorescence imaging of neuritic calcium. J Neurosci Meth 122:109–122CrossRefGoogle Scholar
  58. Glassman AH (1993) Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150:546–553PubMedGoogle Scholar
  59. Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149:1189–1194PubMedGoogle Scholar
  60. Gotti C, Fornasari D, Clementi F (1997) Human neuronal nicotinic receptors. Prog Neurobiol 53:199–237PubMedGoogle Scholar
  61. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713–716PubMedGoogle Scholar
  62. Grenhoff J, Aston-Jones G, Svensson TH (1986) Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128:351–358PubMedGoogle Scholar
  63. Griffith J, Hoffer LD, Adler LE, Zerbe GO, Freedman R (1995) Effects of sound intensity on a mid-latency evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Psychophysiology 32:460–466PubMedGoogle Scholar
  64. Griffith JM, O’Neill J, Petty F, Garver D, Young D, Freedman R (1998) Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44:98–106CrossRefPubMedGoogle Scholar
  65. Grottick A, Higgins G (2000) Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 117:197–208PubMedGoogle Scholar
  66. Grottick A, Wyler R, Higgins G (2000a) The alpha4/beta2 agonist SIB 1765F, but not the alpha7 agonist AR-R 17779, cross-sensitizes to the psychostimulant effects of nicotine. Psychopharmacology 150:233–236CrossRefPubMedGoogle Scholar
  67. Grottick AJ, Trube G, Corrigal WA, Huwyler J, Malherbe P, Wyler R, Higgins GA (2000b) Evidence that nicotinic alpha7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294:1112–1119PubMedGoogle Scholar
  68. Guan Z-Z, Zhang X, Blennow K, Nordberg A (1999) Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10:1779–1782PubMedGoogle Scholar
  69. Gueorguiev VD, Zeman RJ, Meyer EM, Sabban EL (2000) Involvement of alpha7 nicotinic acetylcholine receptors in activation of tyrosine hydroxylase and dopamine beta-hydroxylase gene expression in PC12 cells. J Neurochem 75:1997–2005CrossRefPubMedGoogle Scholar
  70. Hahn B, Sharples CG, Wonnacott S, Shoaib M, Stolerman IP (2003) Attentional effects of nicotinic agonists in rats. Neuropharmacology 44:1054–1067CrossRefPubMedGoogle Scholar
  71. Hakki A, Friedman H, Pross S (2002) Nicotine modulation of apoptosis in human coronary artery endothelial cells. Int Immunopharmacol 2:1403–1409CrossRefPubMedGoogle Scholar
  72. Hershman KM, Freedman R, Bickford PC (1995) GABA-B antagonists diminish the inhibitory gating of auditory response in the rat hippocampus. Neuroscience Letters 190:133–136CrossRefPubMedGoogle Scholar
  73. Heusch WL, Maneckjee R (1998) Signaling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 19:551–556CrossRefPubMedGoogle Scholar
  74. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143:993–997PubMedGoogle Scholar
  75. Hunter BE, De Fiebre CM, Papke RL, Kem WR, Meyer E (1994) A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci Lett 168:130–134CrossRefPubMedGoogle Scholar
  76. Ji D, Dani JA (2000) Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83:2682–2690Google Scholar
  77. Jones S, Sudweeks S, Yakel JL (1999) Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22:555–561CrossRefPubMedGoogle Scholar
  78. Judd LL, McAdams L, Budnick B, Braff DL (1992) Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 149:488–493PubMedGoogle Scholar
  79. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796PubMedGoogle Scholar
  80. Kelly C, McCreadie RG (1999) Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 156:1751–1757PubMedGoogle Scholar
  81. Kem WR (2000) The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer’s disease: studies with DMXBA (GTS-21). Behav Brain Res 113:169–181PubMedGoogle Scholar
  82. Kem WR, Abbott BC, Coates RM (1971) Isolation and structure of a hoplonemertine toxin. Toxicon 9:15–22CrossRefPubMedGoogle Scholar
  83. Kem WR, Mahnir VM, Lin B, Prokai-Tartrai K (1996) Two primary GTS-21 metabolites are potent partial agonists at alpha7 nicotinic receptors expressed in the Xenopus oocyte. Soc Neurosci Abstr 22:268Google Scholar
  84. Kem WR, Mahnir VM, Papke RL, Lingle CJ (1997) Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J Pharmacol Exp Ther 283:979–992PubMedGoogle Scholar
  85. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28:542–551CrossRefPubMedGoogle Scholar
  86. Klein C, Andresen B (1991) On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls. J Psychophysiol 5:361–369Google Scholar
  87. Klein C, Andresen B, Thom E (1993) Blinking, alpha brain waves and smoking in schizophrenia. Acta Psychiatr Scand 87:172–178PubMedGoogle Scholar
  88. Lambe EK, Piccioto MR, Aghajanian GK (2003) Nicotine induced glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28:216–225CrossRefPubMedGoogle Scholar
  89. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH (2000) Smoking and mental illness: a population-based prevalence study. JAMA 284:2606–2610CrossRefPubMedGoogle Scholar
  90. Léna C, Changeux J-P (1998) Allosteric nicotinic receptors, human pathologies. J Physiol (Paris) 92:63–74Google Scholar
  91. Leonard S, Bertrand D (2001) Neuronal nicotinic receptors: from structure to function. Nicotine Tobacco Res 3:203–223CrossRefGoogle Scholar
  92. Leonard S, Gault J, Moore T, Hopkins J, Robinson M, Olincy A, Adler LE, Cloninger CR, Kaufmann CA, Tsuang MT, Faraone SV, Malaspina D, Svrakic DM, Freedman R (1998) Further Investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH genetics initiative. Am J Med Genet 81:308–312PubMedGoogle Scholar
  93. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe GO, Olincy A, Ross RG, Adler LE, Freedman R (2002) Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59:1085–1096CrossRefPubMedGoogle Scholar
  94. Levin ED, Rezvani AH (2000) Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 393:141–146PubMedGoogle Scholar
  95. Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217–230CrossRefPubMedGoogle Scholar
  96. Levin ED, Wilson W, Rose JE, McEvoy J (1996) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429–436PubMedGoogle Scholar
  97. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL (2000) Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 157:767–771PubMedGoogle Scholar
  98. Liu C-M, Hwu H-G, Lin M-W, Ou-Yang W-C, Lee SF-C, Fann CSJ, Wong S-H, Hsieh S-H (2001) Suggestive evidence for linkage of schizophrenia to markers at chromosome 15q13–14 in Taiwanese families. Am J Med Genet 105:658–661PubMedGoogle Scholar
  99. Luntz-Leybman V, Bickford PC, Freedman R (1992) Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587:130–136PubMedGoogle Scholar
  100. Lyons MJ, Bar JL, Kreman WS, Toomey R, Eisen SA, Goldberg J, Faraone SV, Tsuang M (2002) Nicotine and familial vulnerability to schizophrenia: a discordant twin study. J Abnorm Psychol 111:687–693CrossRefPubMedGoogle Scholar
  101. Machu TK, Hamilton ME, Frye TF, Shanklin CL, Harris MC, Sun H, Tenner Jr. TE, Soti FS, Kem WR (2001) Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine-3A receptor. J Pharmacol Exp Ther 299:1112–1119PubMedGoogle Scholar
  102. Marutle A, Zhang X, Court J, Piggot M, Johnson M, Perry R, Perry E, Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22:115–126CrossRefPubMedGoogle Scholar
  103. Masterson E, O’Shea B (1984) Smoking and malignancy in schizophrenia. Br J Psychiatry 145:429–432PubMedGoogle Scholar
  104. McEvoy JP, Freudenreich O, Wilson W (1999) Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46:125–129CrossRefPubMedGoogle Scholar
  105. Meyer EM, De Fiebre CM, Hunter BE, Simpkins CE, Frauworth N, De Fiebre NEC (1994) Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev Res 31:127–134Google Scholar
  106. Meyer EM, Tay ET, Papke RL, Meyers C, Huang G-l, De Fiebre CM (1997) 3-2,4-Dimethoxybenzylidene-anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 768:49–56CrossRefPubMedGoogle Scholar
  107. Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL (1998a) Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha7 nicotinic receptors. J Pharmacol Exp Ther 287:918–925PubMedGoogle Scholar
  108. Meyer EM, Tay ET, Zoltewicz JA, Meyers C, King MA, Papke RL, De Fiebre CM (1998b) Neuroprotective and memory-related actions of novel alpha7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther 284:1026–1032PubMedGoogle Scholar
  109. Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J, Mack R, Loch III J, Wu E, Kover A, Verhoest P, Sampognaro A, Phillips E, Zhu Y, Murray R, Griffith R, Blosser J, Gurley D, Machulskis A, Zongrone J, Rosen A, Gordon J (2000) (−)-Spiro[1-azabicyclo[2.2.2]octane-3,5’-oxazolidin-2’-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha7 nicotinic acetylcholine receptor. J Med Chem 43:4045–4050CrossRefPubMedGoogle Scholar
  110. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G, Hea R, Griffith J (1999) Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 39:10–17PubMedGoogle Scholar
  111. Nanri M, Yamamoto J, Miyake H, Watanabe H (1998) Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn J Pharmacol 76:23–29CrossRefPubMedGoogle Scholar
  112. Neves-Pereira M, Bassett AS, Honer WG, Lang D, King NA, Kennedy JL (1998) No evidence for linkage of the CHRNA7 gene region in Canadian schizophrenia families. Am J Med Gen 81:361–363PubMedGoogle Scholar
  113. Nisell M, Nomikos GG, Svensson TH (1995) Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76:157–162PubMedGoogle Scholar
  114. Nomikos GG, Schilström B, Hildebrand BE, Panagis G, Grenhoff J, Svensson TH (2000) Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav Brain Res 113:97–103PubMedGoogle Scholar
  115. Olincy A, Young DA, Freedman R (1997) Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 42:1–5CrossRefPubMedGoogle Scholar
  116. Olincy A, Ross RG, Young DA, Roath M, Freedman R (1998) Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 18:175–185CrossRefPubMedGoogle Scholar
  117. Olincy A, Johnson LL, Ross RG (2003) Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 117:223–236CrossRefPubMedGoogle Scholar
  118. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z, Brunner D (2001) The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology 156:284–290Google Scholar
  119. Papke RL, Meyer E, Nutter T, Uteshev VV (2000) Alpha-7 receptor-selective agonists and modes of alpha7 receptor activation. Eur J Pharmacol 393:179–195CrossRefPubMedGoogle Scholar
  120. Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75–111PubMedGoogle Scholar
  121. Pérez de la Mora M, Mendez-Franco J, Salceda R, Aguirre JA, Fuxe K (1991) Neurochemical effects of nicotine on glutamate and GABA mechanisms in the rat brain. Acta Physiol Scand 141:241–250PubMedGoogle Scholar
  122. Piccioto MR, Caldarone BJ, King SL, Zachariou V (2000) Nicotinic Receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 22:451–465CrossRefPubMedGoogle Scholar
  123. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T, Williamson R, Collier D, Murray R (2000) Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet 96:196–201PubMedGoogle Scholar
  124. Ross RG, Olincy A, Harris JG, Radant A, Hawkins M, Adler LE, Freedman R (1999) Evidence for bilineal inheritance of physiological indicators of risk in childhood-onset schizophrenia. Am J Med Genet 88:188–199CrossRefPubMedGoogle Scholar
  125. Rosse RB, Deutsch SI (2002) Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25:272–275CrossRefPubMedGoogle Scholar
  126. Schreiber R, Dalmus M, De Vry J (2002) Effects of the alpha4/beta2 and alpha7 nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 159:248–257CrossRefPubMedGoogle Scholar
  127. Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK (2002) The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 52:721–728CrossRefPubMedGoogle Scholar
  128. Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus. Neuropsychopharmacology 26:583–594Google Scholar
  129. Siegal C, Waldo MC, Mizner G, Adler LE, Freedman R (1984) Deficits in sensory gating in schizophrenic patients and their relatives. Arch Gen Psychiatry 41:607–612PubMedGoogle Scholar
  130. Simosky JK, Stevens KE, Kem WR, Freedman R (2001) Intragastric DMXBA, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 50:493–500CrossRefPubMedGoogle Scholar
  131. Simosky JK, Stevens KE, Adler LE, Freedman R (2003) Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology 165:386–396PubMedGoogle Scholar
  132. Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002) Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27:479–497CrossRefPubMedGoogle Scholar
  133. Stevens KE, Wear KD (1997) Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 57:869–874PubMedGoogle Scholar
  134. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM (1996) Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15:152–162Google Scholar
  135. Stevens KE, Kem WR, Mahnir VM, Freedman R (1998) Selective alpha7 nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136:320–327CrossRefPubMedGoogle Scholar
  136. Stevens KE, Kem WR, Freedman R (1999) Selective alpha7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice. Biol Psychiatry 46:1443–1450CrossRefPubMedGoogle Scholar
  137. Summers KL, Giacobini E (1995) Effects of local and repeated systemic administration of (–)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 20:753–759PubMedGoogle Scholar
  138. Summers KL, Cuadra G, Naritoku D, Giacobini E (1994) Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex. Drug Dev Res 31:108–119Google Scholar
  139. Summers KL, Kem WR, Giacobini E (1997) Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn J Pharmacol 74:139–146PubMedGoogle Scholar
  140. Svensson TH, Grenhoff J, Engberg G (1990) Effect of nicotine on dynamic function of brain catacholamine neurons. Ciba Foundation Symposium 152:169–180PubMedGoogle Scholar
  141. Taiminen TJ, Salokangas RKR, Saarijärvi S, Niemi H, Lehto H, Ahola V, Syvälahti E (1998) Smoking and cognitive deficits in schizophrenia: a pilot study. Addict Behav 23:263–266CrossRefPubMedGoogle Scholar
  142. Tani Y, Saito K, Imoto M, Ohno T (1998) Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain- an in vivo microdialysis study. Eur J Pharmacol 351:181–188PubMedGoogle Scholar
  143. Tsuang DW, Skol AD, Faraone SV, Bingham S, Young KA, Prabhudesai S, Haverstock SL, Mena F, Menon AS, Bisset D, Pepple J, Sauter F, Baldwin C, Weiss D, Collins J, Boehnke M, Schellenberg GD, Tsuang MT (2001) Examination of genetic linkage of chromosome 15 to schizophrenia in a large Veterans Affairs Cooperative Study sample. Am J Med Gene 105:662–668PubMedGoogle Scholar
  144. Tung C-S, Grenhoff J, Svensson TH (1990) Nicotine counteracts midbrain dopamine cell dysfunction induced by prefrontal cortex inactivation. Acta Physiol Scand 138:427–428PubMedGoogle Scholar
  145. Van Haaren F, Anderson KG, Haworth SC, Kem WR (1999) GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav 64:439–444Google Scholar
  146. Venables PH (1992) Hippocampal function and schizophrenia: experimental psychological evidence. Ann N Y Acad Sci 658:111–127PubMedGoogle Scholar
  147. Vidal C (1994) Nicotinic potentiation of glutamatergic synapses in the prefrontal cortex: new insight into the analysis of the role of nicotinic receptors in cognitive functions. Drug Dev Res 31:120–126Google Scholar
  148. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE, Nagamoto HT, Wender P, Byerley W, Plaetke R, Freedman R (1991) Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res 39:257–268CrossRefPubMedGoogle Scholar
  149. Waldo MC, Cawthra E, Adler LE, Dubester S, Staunton M, Nagamoto HT, Baker N, Madison A, Simon J, Scherzinger A, Drebing C, Gerhardt G, Freedman R (1994) Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophr Res 12:93–106PubMedGoogle Scholar
  150. Ward PB, Hoffer LD, Liebert B, Catts SV, O’Donnell M, Adler LE (1996) Replication of a P50 auditory sensory gating deficit in Australian patients with schizophrenia. Psychiatry Res 64:121–135CrossRefPubMedGoogle Scholar
  151. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111:81–90CrossRefPubMedGoogle Scholar
  152. Westfall TC, Grant H, Perry H (1983) Release of dopamine and 5-hhdroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 14:321–325CrossRefPubMedGoogle Scholar
  153. Wheeler JW, Olubajo O, Storm CB (1981) Anabaseine: venom alkaloid of aphaenogaster ants. Science 211:1051–1052Google Scholar
  154. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG (1989) Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 79:157–163PubMedGoogle Scholar
  155. Woodruff-Pak DS (2003) Mecamylamine reversal by nicotine and by a partial alpha7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning. Behav Brain Res 143:159–167CrossRefPubMedGoogle Scholar
  156. Woodruff-Pak DS, Li Y-T, Kem WR (1994) A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res 645:309–317PubMedGoogle Scholar
  157. Xu J, Pato MT, Dalla Torre C, Medeiros H, Carvalho C, Basile VS, Bauer A, Dourado A, Valente J, Soares MJ, Macedo AA, Coelho I, Ferreira CP, Azevedo MH, Macciardi F, Kennedy JL, Pato CN (2001) Evidence of linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am J Med Genet 105:669–674PubMedGoogle Scholar
  158. Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP (2002) Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 27:684–686PubMedGoogle Scholar
  159. Yee CM, Nuechterlein KH, Morris SE, White PM (1998) P50 Suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 107:691–698CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Laura F. Martin
    • 1
  • William R. Kem
    • 2
  • Robert Freedman
    • 1
  1. 1.Department of PsychiatryDepartment of Veterans Affairs and University of Colorado Health Sciences CenterDenverUSA
  2. 2.Department of Pharmacology and Therapeutics, College of MedicineUniversity of FloridaGainesvilleUSA

Personalised recommendations